Patents by Inventor Ryan Erik Holcomb

Ryan Erik Holcomb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE ANTI-OSMR ANTIBODY FORMULATION
    Publication number: 20250114449
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Application
    Filed: May 23, 2024
    Publication date: April 10, 2025
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
  • C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
    Patent number: 11534482
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: December 27, 2022
    Assignee: VIROPHARMA BIOLOGICS LLC
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
    Patent number: 11364288
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: June 21, 2022
    Assignee: VIROPHARMA BIOLOGICS LLC
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • Stable Anti-OSMR Antibody Formulation
    Publication number: 20220062414
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Application
    Filed: September 8, 2021
    Publication date: March 3, 2022
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
  • High concentration formulations of adalimumab
    Patent number: 11229702
    Abstract: The present invention relates to aqueous pharmaceutical compositions comprising a high concentration (i.e., greater than 50 milligrams per milliliter) of adalimumab (including antibody proteins considered or intended as “biosimilar” or “bio-better” variants of commercially available adalimumab) suitable for long-term storage, and methods of manufacture of the compositions; methods of their administration; and articles containing the same.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: January 25, 2022
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Ryan Erik Holcomb
  • Stable anti-OSMR antibody formulation
    Patent number: 11141479
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: October 12, 2021
    Assignee: KINIKSA PHARMACEUTICALS, LTD.
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
  • C1-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY
    Publication number: 20200261556
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Application
    Filed: October 2, 2019
    Publication date: August 20, 2020
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • Stable Anti-OSMR Antibody Formulation
    Publication number: 20200061188
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Application
    Filed: August 26, 2019
    Publication date: February 27, 2020
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
  • Stable anti-OSMR antibody formulation
    Patent number: 10493149
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: December 3, 2019
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
  • Stable anti-OSMR antibody formulation
    Patent number: 10391170
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: August 27, 2019
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
  • C1-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY
    Publication number: 20190160157
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Application
    Filed: August 2, 2018
    Publication date: May 30, 2019
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • C1-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY
    Publication number: 20190160158
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficienty are disclosed.
    Type: Application
    Filed: September 5, 2018
    Publication date: May 30, 2019
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • STABLE ANTI-OSMR ANTIBODY FORMULATION
    Publication number: 20190054169
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Application
    Filed: November 2, 2018
    Publication date: February 21, 2019
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
  • C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
    Patent number: 10201595
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: February 12, 2019
    Assignee: Shire ViroPharma Incorporated
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • STABLE ANTI-OSMR ANTIBODY FORMULATION
    Publication number: 20180333489
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Application
    Filed: April 11, 2018
    Publication date: November 22, 2018
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M. Levesque, Ryan Erik Holcomb
  • C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
    Patent number: 10130690
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: November 20, 2018
    Assignee: Shire ViroPharma Incorporated
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
    Patent number: 10105423
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: October 23, 2018
    Assignee: Shire ViroPharma Incorporated
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
    Patent number: 10080788
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: September 25, 2018
    Assignee: Shire ViroPharma Incorporated
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • C1-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY
    Publication number: 20180153972
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Application
    Filed: December 11, 2017
    Publication date: June 7, 2018
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • C1-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY
    Publication number: 20180110844
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Application
    Filed: December 11, 2017
    Publication date: April 26, 2018
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb